1. Home
  2. VNO vs CORT Comparison

VNO vs CORT Comparison

Compare VNO & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vornado Realty Trust

VNO

Vornado Realty Trust

HOLD

Current Price

$37.88

Market Cap

6.3B

Sector

Real Estate

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

N/A

Current Price

$117.10

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VNO
CORT
Founded
1946
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
9.7B
IPO Year
1994
2001

Fundamental Metrics

Financial Performance
Metric
VNO
CORT
Price
$37.88
$117.10
Analyst Decision
Hold
Buy
Analyst Count
10
5
Target Price
$33.00
$96.50
AVG Volume (30 Days)
1.7M
1.2M
Earning Date
05-04-2026
04-30-2026
Dividend Yield
2.52%
N/A
EPS Growth
10400.00
N/A
EPS
N/A
0.09
Revenue
$1,810,425,000.00
$761,407,000.00
Revenue This Year
N/A
$26.08
Revenue Next Year
$5.42
$26.98
P/E Ratio
N/A
$1,271.89
Revenue Growth
1.27
12.79
52 Week Low
$24.57
$28.66
52 Week High
$43.37
$122.21

Technical Indicators

Market Signals
Indicator
VNO
CORT
Relative Strength Index (RSI) 44.72 66.55
Support Level $37.94 $76.41
Resistance Level $39.27 $122.21
Average True Range (ATR) 1.15 5.00
MACD -0.23 -0.00
Stochastic Oscillator 0.30 81.48

Price Performance

Historical Comparison
VNO
CORT

About VNO Vornado Realty Trust

Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: